|(what is this?)|
Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.
Rilonacept was given an "orphan drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome and neonatal onset multisystem inflammatory disease (It is not approved in the U.S. on this indication).
- Terkeltaub, R; Sundy, J S; Schumacher, H R; Murphy, F; Bookbinder, S; Biedermann, S; Wu, R; Mellis, S; Radin, A (2009). "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study". Annals of the Rheumatic Diseases. 68 (10): 1613–1617. doi:10.1136/ard.2009.108936. PMC 2732898. PMID 19635719.
- "Molecule of the month. Rilonacept". Drug News & Perspectives. 21 (4): 232. 2008. PMID 18560622.
- "Arcalyst FDA Approval History - Drugs.com". Archived from the original on 2012-05-16. Retrieved 2012-05-08.
- "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". Archived from the original on 2012-05-21. Retrieved 2012-05-08.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|